Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model

Cancer Gene Therapy
C-P DayM-C Hung

Abstract

To ensure the success of systemic gene therapy, it is critical to enhance the tumor specificity and activity of the promoter. In the current study, we determined that topoisomerase IIalpha promoter is selectively activated in breast cancer cells. An element containing an inverted CCAAT box (ICB) was shown to be responsible for the breast cancer specificity. When the ICB-harboring topoisomerase IIalpha minimal promoter was linked with an enhancer sequence from the cytomegalovirus immediate early gene promoter (CMV promoter), this composite promoter, CT90, exhibited activity comparable to or higher than the CMV promoter in breast cancer cells in vitro and in vivo, yet expresses much lower activity in normal cell lines and normal organs than the CMV promoter. A CT90-driven construct expressing BikDD, a potent proapoptotic gene, was shown to selectively kill breast cancer cells in vitro, and to suppress mammary tumor development in an animal model of intravenously administrated, liposome-delivered gene therapy. Expression of BikDD was readily detectable in the tumors but not in the normal organs (such as heart) of CT90-BikDD-treated animals. The results indicate that liposomal CT90-BikDD is an effective systemic breast cancer-targe...Continue Reading

References

Aug 1, 1995·British Journal of Cancer·C T BaillieN J Bradley
Mar 10, 1995·The Journal of Biological Chemistry·S KurachiK Kurachi
Dec 24, 1993·Science·S van den Heuvel, E Harlow
Jul 1, 1997·Nature Biotechnology·N S TempletonG N Pavlakis
Apr 29, 1998·The Journal of Clinical Investigation·G ThurstonD M McDonald
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y N ChenW G Kaelin
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S PandhaN R Lemoine
May 16, 2000·Advances in Experimental Medicine and Biology·M C HungN T Ueno
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G N HortobagyiM C Hung
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Nov 27, 2001·Science·E Marshall
Dec 4, 2001·Advanced Drug Delivery Reviews·Y S Haviv, D T Curiel
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Jul 27, 2002·Science·John Rouse, Stephen P Jackson
Jul 27, 2002·Science·Richard D KolodnerKyungjae Myung
Jul 27, 2002·Science·Richard S Maser, Ronald A DePinho
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Dec 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Huanzhang LuNancy Smyth Templeton
Jun 20, 2003·Cell Proliferation·Katrien VermeulenZwi N Berneman
Aug 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Christos SotiriouEdison T Liu
May 25, 2004·Expert Opinion on Biological Therapy·Kirsi Saukkonen, Akseli Hemminki
Jan 11, 2005·Current Gene Therapy·Youngsuk YiKwan Hee Lee

❮ Previous
Next ❯

Citations

Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jer-Yen Yang, Mien-Chie Hung
Aug 13, 2009·Molecular Cancer Therapeutics·Xiaoming XieMien-Chie Hung
Nov 4, 2009·Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences·Ludovic Mailleret, Valérie Lemesle

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.